All In Biotech

Drug Trial Radar · NCT07741240

A Study of KH607 as Monotherpy in Adults Participants With Major Depressive Disorder

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of KH607 Tablets in the Treatment of Major Depressive Disorder

Last checked: Nov 19, 2026Latest source record: Aug 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 232 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

232

Planned (sponsor's estimate)

Start

Jul 2026

Primary completion

Dec 2027

Study completion Dec 2027

Sponsor

Sponsor type
Industry
First posted
Aug 3, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial includes a short-term study and a long-term study. The short-term study is a multicenter, randomized, double-blind, placebo-controlled parallel-group study with a 6-week duration. The long-term study is a multicenter, open-label, single-arm study with a maximum duration of 27 weeks.

Conditions

  • Major Depressive Disorder (MDD)

Interventions

  • KH607 tabletsDrug

    oral 20mg, once daily for 21 days

  • placeboDrug

    oral, once daily for 21 days

  • KH607 tabletsDrug

    oral 20mg, once daily for 21 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Double Blind (DB) Treatment Phase: Change from Baseline in 17-item Hamilton Rating Scale for Depression (HAM-D17) Total Score in Participants with Major Depressive DisorderTime frame: Baseline up to Day 22

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.